Duke-NUS Graduate Medical School, Singapore, Republic of Singapore.
Singapore National Eye Center, Singapore, Republic of Singapore; Singapore Eye Research Institute, Singapore, Republic of Singapore.
Ophthalmology. 2013 Mar;120(3):464-470. doi: 10.1016/j.ophtha.2012.08.024. Epub 2012 Nov 20.
Selective endothelial transplantation in the form of Descemet's stripping endothelial keratoplasty (DSEK) is rapidly replacing traditional full-thickness penetrating keratoplasty (PK) for endothelial disease. An incremental cost-effectiveness analysis was performed to determine whether the benefits of DSEK are worth the additional costs.
Retrospective cohort study.
Patients at the Singapore National Eye Center, a tertiary eye center in Singapore, with Fuchs' dystrophy or bullous keratopathy who underwent either PK or DSEK.
Patients underwent either PK (n = 171) or DSEK (n = 93) from January 2001 through December 2007. Data were collected from inpatient and outpatient notes corresponding to the time immediately before the procedure to up to 3 years after.
Improvements in best spectacle-corrected visual acuity were used to calculate the increase in quality-adjusted life years (QALYs) 3 years after the procedure. This was combined with hospital charges (a proxy for costs) to determine incremental cost-effectiveness ratios (ICERs) comparing PK with no intervention and DSEK with PK.
Three-year charges for DSEK and PK were $7476 and $7236, respectively. The regression-adjusted improvement in visual acuity for PK relative to no intervention was -0.613 logarithm of the minimum angle of resolution (logMAR) units (P<0.001), and for DSEK relative to PK, it was -0.199 logMAR units (P = 0.045). The regression-adjusted marginal gain in utility for PK relative to no intervention was 0.128 QALYs (P<0.001) and for DSEK relative to PK was 0.046 QALYs (P = 0.031). This resulted in ICERs of $56 409 per QALY for PK relative to no intervention and $5209 per QALY for the more expensive DSEK relative to PK.
If the goal is to maximize societal health gains given fixed resources, DSEK should be the preferred strategy. For a fixed budget, it is possible to achieve greater QALY gains by providing DSEK to as many patients as possible (and nothing to others), rather than providing PK.
以撕囊的内皮角膜移植术(Descemet's stripping endothelial keratoplasty,DSEK)的形式进行选择性内皮移植术正在迅速取代传统的全层穿透性角膜移植术(penetrating keratoplasty,PK)治疗角膜内皮疾病。本研究进行了增量成本效益分析,以确定 DSEK 的益处是否超过了额外的成本。
回顾性队列研究。
新加坡国家眼科中心的患者,这些患者为新加坡的一家三级眼科中心,患有 Fuchs 角膜营养不良或大泡性角膜病变,他们接受了 PK 或 DSEK 治疗。
2001 年 1 月至 2007 年 12 月期间,患者接受了 PK(n = 171)或 DSEK(n = 93)治疗。数据来自于手术前即刻至术后 3 年的住院和门诊记录。
术后 3 年最佳矫正视力的改善情况用于计算术后 3 年质量调整生命年(quality-adjusted life years,QALYs)的增加。这与医院费用(成本的代理)相结合,以确定与 PK 相比无干预和 DSEK 与 PK 相比的增量成本效益比(incremental cost-effectiveness ratios,ICERs)。
DSEK 和 PK 的 3 年费用分别为 7476 美元和 7236 美元。与无干预相比,PK 矫正视力的回归调整后改善为-0.613 对数最小角分辨率单位(logMAR)(P<0.001),与 PK 相比,DSEK 的改善为-0.199 logMAR 单位(P = 0.045)。与无干预相比,PK 矫正后效用的回归调整边际获益为 0.128 QALYs(P<0.001),与 PK 相比,DSEK 的获益为 0.046 QALYs(P = 0.031)。这导致 PK 与无干预相比的 ICER 为每 QALY 56409 美元,DSEK 与 PK 相比的 ICER 为每 QALY 5209 美元。
如果目标是在固定资源下最大化社会效益,DSEK 应该是首选策略。在固定预算的情况下,通过尽可能多地为患者提供 DSEK(而不是为其他人提供)来获得更大的 QALY 获益,而不是提供 PK,这是可能的。